BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Thermo Fisher’s Integrated CDMO-CRO Model Cuts Drug Development Time by Up to 34 Months, Finds Tufts CSDD Study

Thermo Fisher Scientific Inc., the world leader in serving science, announced the findings of new research by the Tufts Center for the Study of Drug ...

June 17, 2025 | News

66 Percent of APAC Patients Face Specialist Delays as Philips Urges Trust in AI to Ease Healthcare Pressures

66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days 89% of healt...

June 13, 2025 | Report

Eluminex Reports Positive Phase 1 Results for EB-105 in Diabetic Macular Edema Patients

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels No Safety Issues Observed...

June 10, 2025 | News

New Studies Presented at ERA 2025 Reinforce NEFECON®’s Early Intervention Value in IgA Nephropathy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust su...

June 09, 2025 | News

ASCO 2025 Showcases New Oncology Paradigms, From Breast Cancer Breakthroughs to AI-Led Precision Medicine

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t just another scientific gathering and it was a seismic event that redrew ...

June 06, 2025 | Report

Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

June 05, 2025 | News

Protagonist Therapeutics and Takeda Report Positive Phase 3 Results for Rusfertide in PV, Meeting All Primary and Secondary Endpoints

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phleboto...

June 03, 2025 | News

NICE Recommends CSL Vifor’s Sparsentan for Routine Use in Treating IgA Nephropathy in England

CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending tha...

May 26, 2025 | News

AnnJi Reports Promising Phase 1/2a Results for AJ201 in Rare Neuromuscular Disease SBMA

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and r...

May 22, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

May 21, 2025 | News

Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer

Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...

May 19, 2025 | News

Shanghai Ark Biopharmaceutical Announces Positive Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis

Shanghai Ark Biopharmaceutical Co., Ltd. announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of id...

May 16, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

May 12, 2025 | News

Connext Completes Phase 1 for CNT201, Eyes Phase 2 Launch and Expansion into Peyronie’s Disease

Conducted under U.S. FDA-cleared IND– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease Connext, a clinical s...

May 09, 2025 | News

Stay Connected